Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CBMG Raises $120 Million for Clinical Trials of Cellular Immunotherapies

publication date: Oct 1, 2021

CBMG, a Maryland-Shanghai biopharma, raised $120 million in a Series A funding to develop its immunoncology programs. CBMG develops novel cellular immunotherapies to treat cancer and degenerative diseases, with an emphasis on CAR-T products for cancer and stem cell therapies for degenerative diseases. In February 2021, CBMG completed a $383 million go-private transaction from its previous NASDAQ listing. The A round was led by AstraZeneca-CICC Fund, Sequoia Capital China and Yunfeng Capital. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital